New advances in the treatments of drug-resistant tuberculosis.
Mohanad MahmoudYu-Rong TanPublished in: Expert review of anti-infective therapy (2023)
It is necessary to determine the function of individual gene alterations in drug-resistant TB. A combination of the most recent anti-TB drugs, such as bedaquiline and delamanid, is recommended. Longitudinal studies and animal model experiments with some medicinal plant extracts are required for better results. Nanotechnology has the potential to reduce drug side effects. Useful efficacy of phage therapy and CRISPR-cas9 technology as adjunct therapies for the management of drug-resistant TB.
Keyphrases
- drug resistant
- mycobacterium tuberculosis
- multidrug resistant
- crispr cas
- acinetobacter baumannii
- genome editing
- pulmonary tuberculosis
- pseudomonas aeruginosa
- genome wide
- hiv aids
- adverse drug
- copy number
- emergency department
- dna methylation
- bone marrow
- cystic fibrosis
- hepatitis c virus
- transcription factor
- antiretroviral therapy